We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Design Intricacies and Decision Making Strategy for Drug Drug Interaction Studies

SEKISUI XenoTech

Presenter: Andrew G. Taylor, Ph.D., Manager of Technical Support for Services at XenoTech


Conducting in vitro ADME drug-drug interaction (DDI) studies early on in the drug development process is more than simply a box checking exercise to satisfy regulatory requirements. The information provided by these studies provides a deeper understanding of the molecule to the drug developer helping to inform go or no-go decisions early on.


Additionally, these studies are important to help prepare for clinical studies by providing data for FIH dose prediction and potential DDI risks. While in vitro ADME DDI studies might appear deceptively simple, maximizing the information gained from them can be complex, and benefits greatly form expert design and interpretation.


In this presentation we will discuss the main types of in vitro ADME studies that are required by the regulatory agencies, timing on when to conduct these studies, and highlight the importance of proper study design and data analysis.


Request a copy of the slides:

https://www.xenotech.com/about/events/webinar-design-intricacies-and-decision-making-strategy-for-drug-drug-interaction-studies/

Questions, comments and requests: https://www.xenotech.com/contact-us

More information on our research services and test systems: https://www.xenotech.com

Other previously aired webinars: https://www.xenotech.com/scientific-resources/webinar-series

Upcoming webinar notifications: https://www.xenotech.com/newsletter-signup

Request a webinar topic: https://www.xenotech.com/scientific-resources/upcoming-webinars


About the Presenter:

Dr. Andrew G. Taylor received his Ph.D. from University of California San Diego. He joined XenoTech as a research scientist in 2017, serving as a Study Director in nonclinical drug interaction contract studies compliance with Good Laboratory in Practices (GLP), OECD Principles of GLP, &/or Japan MOHW GLP Standards and specializing in drug transport and drug metabolism studies. He became the Technical Support Manager for services in 2020 and provides valuable guidance to ensure research needs are being met.

Advertisement